In terms of revenue, the Global Pyrogen Testing Market is expected to reach by 2030, growing at a CAGR (Compound Annual Growth Rate) of 13.2% from 2023 to 2030.
has become a crucial practice employed by pharmaceutical, biotechnology, and various drug manufacturing companies to ensure the safe production and release of products free from contamination into the market. In the realm of biotechnology, it plays a pivotal role in supporting research and development endeavors aimed at pioneering new healthcare and biological applications. Consequently, it is poised to emerge as a critical factor in identifying microbial presence or metabolites in drugs during manufacturing.
The escalating demand for products and establishing strategic partnerships are expected to drive market growth. For example, Fujifilm Wako Chemicals offers specialized instruments for endotoxin testing, such as the Toxinometer ET-6000. This instrument incorporates three primary testing methods: Gel-clot, KTA (Kinetic Turbidimetric Assay), and KCA (Kinetic Chromogenic Assay). Notably, the Toxinometer's capacity to initiate a new assay while another is still running streamlines the testing process, facilitating sample retesting. Furthermore, Fujifilm Wako Chemicals planned the launch of the Toxinometer ET-7000 Series in 2019, featuring a user-friendly computer-operated design. These product innovations contribute significantly to market expansion.
Key Highlights from the Report
- Based on Product & Services, the Assays, Kits, & Reagents segment dominates the Pyrogen Testing market owing to the growing preferences for kit-based testing and the ever-increasing need for assays, kits, & reagents.
- Based on Test Type, the LAL Tests segment accounted for the substantial growth of the market in 2022 owing to its rising demand for animal-free detection tests and its high reliability and reproducibility during detection.
- Based on End User, the pharmaceutical & biotechnology companies sector dominated the market in 2022 due to the increasing manufacturing of medicines, biopharmaceuticals, and other biologic products.
- Due to the existence of numerous prominent biotechnology and biopharmaceutical companies, including Pfizer Inc., F. Hoffmann-La Roche AG, Merck Group, Celgene Corp., and Amgen Inc., North America holds a sizable market share in the keyword market in 2022.
The market is primarily propelled by the growing demand for products within the pharmaceutical and biotechnology sectors, coupled with an uptick in research and development investment within the life sciences industry. The emergence of the COVID-19 pandemic has further heightened the demand for techniques over the past decade, driven by the escalating prevalence of infectious diseases. This surge in infectious diseases is expected to continue during the forecast period, consequently driving the demand for . The utilization of endotoxin identification products has played a crucial role in enhancing the management of infectious diseases, particularly in regions with limited healthcare infrastructure. This positive impact on disease management has spurred an increased adoption of products, contributing to the market's growth.
Moreover, the substantial increase in research and development expenditure has played a pivotal role in propelling overall market growth. According to the 2019 European Federation of Pharmaceutical Industries and Associations (EFPIA) report, the pharmaceutical industry in Europe invested approximately EUR 36,500 million in research and development in 2018. Thanks to the burgeoning pharmaceutical and biotechnology industries, the market is anticipated to grow at a high rate. In essence, remains an indispensable practice for pharmaceutical, biotech, and drug manufacturing companies, ensuring the integrity of their products as they enter the market.
North America is accounted to dominate the global Market in terms of market share. This dominance in the North American Market results from several factors, including significant investments in biopharmaceutical and pharmaceutical research, increased drug approvals, the development of pharmaceutical drug pipelines, and raised consumer awareness of product safety.
The Global Pyrogen Testing Market is Segmented as follows
- Product & Service
- Assays, Kits, & Reagents
- Test Type
- LAL Tests
- In Vitro Tests
- Rabbit Tests
- End User
- Pharmaceutical & Biotechnology Companies
- Medical Device Companies
- Other End Users
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
List of the Key Players of the Global Pyrogen Testing Market is
Associates of Cape Cod Inc. (U.S.), BioMerieux SA (France), Charles River Laboratories Inc. (U.S.), Ellab AS (Denmark), Genscript Biotech Corp. (U.S.), Lonza Group AG (Switzerland), Merck KGAA (Germany), Thermo Fisher Scientific Inc. (U.S.), Fujifilm Holdings Corporation (Japan), WUXI Pharmatech (Cayman) Inc. (China), Eurofins Scientific (Luxembourg), Microcoat Biotechnologie GmbH (Germany), Sotera Health (U.S.), Sanquin (Netherlands), Pyrostar (U.S.)
The Global Pyrogen Testing Market Scope can be Tabulated as below
|Market Size Provided for Years||2017 - 2030|
|Historic Years||2017 - 2021|
|Forecast Years||2023 - 2030|
|Regions & Counties Covered||
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis|